eyecro COO Dr. Rafal Farjo to Chair Upcoming Conference

ByConnor Hodde

The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common goal of bringing new and innovative treatments to patients in the area of ophthalmology. Dr. Farjo will present and chair several sessions at upcoming conference.

More on the conference here.

Similar Posts

Groundbreaking Research Published in Collaboration with the National Eye Institute

ByConnor Hodde

We are thrilled to announce the publication of our latest research in eLife. This milestone represents an inspiring collaboration between EyeCRO and the esteemed laboratory of Dr. Anand Swaroop at the National Eye Institute. Our partnership exemplifies how teamwork and shared vision can advance the frontiers of science and medicine, particularly in the development of…

eyecro co-authors paper in Molecular and Cellular Biology studying mechanisms leading to Diabetic Retinopathy

ByConnor Hodde

Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the blood, but it is also an adipokine with retinol-independent, pro-inflammatory activity associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease.  Here we show that RBP4-Tg mice develop progressive retinal degeneration, characterized by photoreceptor ribbon synapse deficiency and subsequent bipolar…

Eleven Biotherapeutics Completes Enrollment of EBI-005 in Patients with Dry Eye Disease

ByConnor Hodde

Eleven Biotherapeutics (EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease. EBI-005, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven’s lead drug candidate in development…

Scientists Successfully Apply Gene Therapy against Retinitis Pigmentosa

ByConnor Hodde

A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder.

  These findings are significant because they open up a new line of research to prevent nerve…

ByConnor Hodde

Retinitis pigmentosa, a blinding eye disease that is caused by the same genetic defect in both dogs and humans, was successfully corrected by a University of Pennsylvania research team that used gene therapy in afflicted dogs. The retinitis pigmentosa cure holds promise for eventual treatment in humans as well. Both humans and dogs can contract…

Biodegradable nanoparticles slip through mucus

ByConnor Hodde

Researchers at Johns Hopkins University (JHU) have created biodegradable, ultra tiny, nanosized particles that can easily slip through the body’s sticky and viscous mucus secretions to deliver a sustained-release medication cargo. The interdisciplinary team of researchers, led by Justin Hanes of the JHU Center for Nanomedicine, developed the nanoparticles so that they not only penetrate…